Advanced Proteome Therapeutics Stock Cash And Equivalents
| APTCF Stock | USD 0.0002 0.00 0.00% |
Advanced Proteome Therapeutics fundamentals help investors to digest information that contributes to Advanced Proteome's financial success or failures. It also enables traders to predict the movement of Advanced Pink Sheet. The fundamental analysis module provides a way to measure Advanced Proteome's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Advanced Proteome pink sheet.
Advanced |
Advanced Proteome Therapeutics Company Cash And Equivalents Analysis
Advanced Proteome's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Advanced Proteome Cash And Equivalents | 761.6 K |
Most of Advanced Proteome's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Advanced Proteome Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
In accordance with the recently published financial statements, Advanced Proteome Therapeutics has 761.6 K in Cash And Equivalents. This is 99.91% lower than that of the Biotechnology sector and 99.83% lower than that of the Health Care industry. The cash and equivalents for all United States stocks is 99.97% higher than that of the company.
Advanced Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Advanced Proteome's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Advanced Proteome could also be used in its relative valuation, which is a method of valuing Advanced Proteome by comparing valuation metrics of similar companies.Advanced Proteome is currently under evaluation in cash and equivalents category among its peers.
Advanced Fundamentals
| Return On Asset | -1.07 | |||
| Current Valuation | 660.53 K | |||
| Shares Outstanding | 41.13 M | |||
| Shares Owned By Insiders | 10.53 % | |||
| Price To Earning | 2.98 X | |||
| Price To Book | 4.92 X | |||
| Gross Profit | (1.71 K) | |||
| EBITDA | 631.22 K | |||
| Net Income | 759.62 K | |||
| Cash And Equivalents | 761.6 K | |||
| Cash Per Share | 0.02 X | |||
| Total Debt | 227.41 K | |||
| Debt To Equity | 4.65 % | |||
| Current Ratio | 0.55 X | |||
| Book Value Per Share | 0.01 X | |||
| Cash Flow From Operations | (693.58 K) | |||
| Earnings Per Share | 0.02 X | |||
| Number Of Employees | 11 | |||
| Beta | 1.55 | |||
| Market Capitalization | 2.47 M | |||
| Total Asset | 636.41 K | |||
| Z Score | 6.0 | |||
| Net Asset | 636.41 K |
About Advanced Proteome Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Advanced Proteome Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Advanced Proteome using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Advanced Proteome Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| EBR | Centrais Electricas Brasileiras | |
| HE | Hawaiian Electric Industries | |
| VFC | VF Corporation | |
| BVHMF | Vistry Group PLC | |
| S | SentinelOne |
Other Information on Investing in Advanced Pink Sheet
Advanced Proteome financial ratios help investors to determine whether Advanced Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Advanced with respect to the benefits of owning Advanced Proteome security.